Neuphoria Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	-0.01	15.65	-	-	-	-
Gross Profit	-0.01	15.65	-	-	-	-
Selling, General & Admin	7.75	7.77	8.47	8.91	-	-
Research & Development	7.72	9.01	9.42	13.07	-11.04	-4.32
Other Operating Expenses	1.28	-	-	-	-	-
Total Operating Expenses	16.75	16.78	17.89	21.98	-11.04	-4.32
Operating Income	-16.76	-1.13	-17.89	-21.98	11.04	4.32
Interest Income	0.58	0.17	0.22	0.32	0.01	0
Other Non-Operating Income (Expense)	-1.62	0.12	2.09	0.14	-	-
Total Non-Operating Income (Expense)	-1.04	0.29	2.31	0.46	0.01	0
Pretax Income	-17.8	-0.84	-15.58	-21.52	-15.14	-6.66
Provision for Income Taxes	-0.37	-0.47	-0.09	-0.14	-0.13	-0.14
Net Income	-17.43	-0.37	-15.49	-21.38	-15.01	-6.52
Net Income to Common	-6.85	-0.37	-15.49	-21.38	-15.01	-6.52
Shares Outstanding (Basic)	4	2	1	1	1	0
Shares Outstanding (Diluted)	4	2	1	1	1	0
Shares Change (YoY)	161.21%	95.01%	22.38%	8.53%	73.52%	-99.93%
EPS (Basic)	-9.88	-0.23	-18.62	-43.20	-29.79	-16.19
EPS (Diluted)	-11.06	-0.23	-18.62	-43.20	-29.79	-16.19
Shares Outstanding	5.38	1.98	1.1	0.68	0.63	0.47
Free Cash Flow	-17.15	0.08	-14.68	-14.22	-15.01	-5.65
Free Cash Flow Per Share	-4.87	0.05	-17.64	-20.91	-23.95	-15.66
Gross Margin	100.00%	100.00%	-	-	-	-
Operating Margin	126330.00%	-7.21%	-	-	-	-
Profit Margin	131387.00%	-2.36%	-	-	-	-
FCF Margin	129283.00%	0.49%	-	-	-	-
EBITDA	-16.1	-0.47	-17.23	-21.21	11.8	5.6
EBITDA Margin	121333.00%	-2.98%	-	-	-	-
EBIT	-16.76	-1.13	-17.89	-21.98	11.04	4.32
EBIT Margin	126330.00%	-7.21%	-	-	-	-
Effective Tax Rate	2.08%	55.89%	0.56%	0.65%	0.87%	2.11%

SEC Filings: 10-K · 10-Q